title: [Chronic hepatitis B and C in renal graft recipients].
abstract: Clinical and morphological features of chronic hepatitis B (CHB), C (CHC), and B+C (CHB+C) were studied in 283 renal graft recipients. High total bilirubin serum levels were detected significantly more often in CHB and CHB+C patients vs. CHC patients. High ALT activity was noted in 65% of CHB patients and only in 45% of CHC patients (p = 0.003). Stable low activity of hepatitis prevailed in renal recipients; it was noted in 56.7% of CHB patients, 66.2% of CHC patients, and 62% of CHB+C patients. The character of pathomorphological liver changes in chronic viral hepatitis was studied in 53 renal graft recipients using puncture biopsy. Histopathological activity index (HAI, Knodell R.G. et al., 1981) witnessed a more severe liver lesion in CHB vs. CHC and CHB+C. Thus, inflammatory activity in CHB was found to be minimal or low in 13 patients, and moderate or high in 11 patients, whilst a minimal or low activity in CHC or CHB+C was found in 16 and 10 patients, respectively, and a moderate activity was detected only in two and one, respectively (p = 0.016 and 0.024 compared with CHB). Advanced hepatic fibrosis or cirrhosis was significantly more frequent (p = 0.006) in CHB patients (eight out of 24) than in CHC ones (none out of 18). The rate of advanced sclerotic changes in CHB+C was lower (one out of 10 patients) than that in CHB, and similar to CHC. Thus, clinico-morphological manifestations were more prominent in renal graft recipients with CHB vs. CHC.
authors.forename: M L
authors.initials: ML
authors.lastname: Zubkin
authors.forename: E M
authors.initials: EM
authors.lastname: Balakirev
authors.forename: V I
authors.initials: VI
authors.lastname: Chervinko
authors.forename: V B
authors.initials: VB
authors.lastname: Zolotarevskiĭ
authors.forename: F S
authors.initials: FS
authors.lastname: Baranova
authors.forename: V A
authors.initials: VA
authors.lastname: Taranov
authors.forename: I G
authors.initials: IG
authors.lastname: Bakulin
authors.forename: A A
authors.initials: AA
authors.lastname: Stanke
authors.forename: A A
authors.initials: AA
authors.lastname: Evseev
authors.forename: V G
authors.initials: VG
authors.lastname: Novozhenov
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001706:Biopsy; D005260:Female; D005500:Follow-Up Studies; D016174:Hepacivirus / Q000276:immunology; D006510:Hepatitis B Antibodies / Q000276:immunology; D006515:Hepatitis B virus / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000209:etiology* / Q000473:pathology / Q000821:virology; D018937:Hepatitis C Antibodies / Q000276:immunology; D019698:Hepatitis C, Chronic / Q000209:etiology* / Q000473:pathology / Q000821:virology; D006801:Humans; D007676:Kidney Failure, Chronic / Q000601:surgery; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011379:Prognosis; D012307:Risk Factors
chemical_list: D006510:Hepatitis B Antibodies; D018937:Hepatitis C Antibodies